Table 2. Combined evidence table for combined safety and efficacy outcome*.
| Trial | Year | CEA | CAS | MT | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of cases | No. of event | Age (years) | Male (%) | DM (%) | No. of cases | No. of event | Age (years) | Male (%) | DM (%) | No. of cases | No. of event | Age (years) | Male (%) | DM (%) | ||
| ACT 16) | 2005–2013 | 364 | 12 | 67.9 | 56.9 | 32.4 | 1,089 | 41 | 67.7 | 61.2 | 35.6 | - | - | - | - | - |
| CREST7) | 2000–2008 | 587 | 28 | 69.6 | 67.5 | 33.7 | 594 | 36 | 69.0 | 63.8 | 32.6 | - | - | - | - | - |
| Kougias et al.5) | 2011–2013 | 28 | 0 | - | - | 48.5 | 27 | 1 | - | - | 33.3 | - | - | - | - | - |
| SAPPHIRE8)† | 2000–2002 | 120 | 35 | 72.6 | 67.1 | 27.5 | 117 | 25 | 72.5 | 66.9 | 25.3 | - | - | - | - | - |
| Kolos et al.26) | 2009–2013 | 31 | 1 | 67.0 | 65.0 | 29.0 | - | - | - | - | - | 24 | 5 | 66.1 | 83.0 | 21.0 |
| ACST25) | 1993–2003 | 1,560 | 82 | - | 65.4 | 20.3 | - | - | - | - | - | 1,560 | 108 | - | 65.6 | 19.6 |
| ACAS23)‡ | 1987–1993 | 825 | 33 | 68.5 | 66.0 | 25.0 | - | - | - | - | - | 834 | 52 | 67.0 | 66.0 | 21.0 |
| VA24) | 1983–1987 | 211 | 14 | 64.1 | 100.0 | 30.0 | - | - | - | - | - | 233 | 23 | 64.7 | 100.0 | 27.0 |
ACAS = Asymptomatic Carotid Atherosclerosis Study; ACST = Asymptomatic Carotid Surgery Trial; ACT 1 = Asymptomatic Carotid Trial; CAS = carotid artery stenting; CEA = carotid endarterectomy; CREST = Carotid Revascularization Endarterectomy Versus Stenting Trial; DM = diabetes mellitus; MT = medical treatment; SAPPHIRE = Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy; VA = Veterans Affairs.
*Composite outcome of periprocedural death, stroke, myocardial infarction, or nonperiprocedural ipsilateral stroke; †Because data on asymptomatic carotid stenosis were not reported separately, those for the mixed population (patients with symptomatic and asymptomatic carotid stenosis) were presented; ‡Age was estimated from the frequency distribution table.